Pre-operative levels of angiopoietin protein-like 3 (ANGPTL3) in women diagnosed with high-grade serous carcinoma of the ovary

Sep 22, 2026

Upload by Anda

Cancer cells require constant lipid supply to survive and progress. Lipid dependence is reported across cancers, including high-grade serous ovarian carcinoma (HGSOC). ANGPTL3, PCSK9, and Apo CIII modulate lipids and are targeted by therapeutic antibodies, yet their roles in HGSOC remain unclear and their pre-operative levels have not been described. This study measures circulating ANGPTL3, PCSK9, and Apo CIII with lipid profiles to determine associations with HGSOC.

LanguageEnglish

CategoryResearch & Report

FormatPDF

Pages10

Reading Time25 min

AccessFree to download

Abstract

Background

Methods

Results

Conclusions

Wong Chong et al. Lipids in Health and Disease (2024) 23:59 [https://doi.org/10.1186/s12944-024-02038-8](https://doi.org/10.1186/s12944-024-02038-8) Lipids in Health and Disease RESEARCH Open Access Pre-operative levels of angiopoietin protein-like 3 (ANGPTL3) in women diagnosed with high-grade serous carcinoma of the ovary Emilie Wong Chong1,2,3,4, France‑Hélène Joncas2,4, Pierre Douville 1,2,3,4, Dimcho Bachvarov 1,2,3,4, Caroline Diorio1,2,3,4,5, Frédéric Calon6,7, Ann‑Charlotte Bergeron 1, Jonatan Blais1,8, Shuk On Annie Leung3,9, Nabil Georges Seidah10 and Anne Gangloff1,2,3,4,8* Abstract Cancer cells need constant supplies of lipids to survive and grow. Lipid dependence has been observed in various types of cancer, including high‑grade serous ovarian carcinomas (HGSOC), which is a lethal form of gynecological malignancy. ANGPTL3, PCSK9, and Apo CIII are pivotal lipid‑modulating factors, and therapeutic antibodies have been developed against each one (Evinacumab, Evolocumab andVolanesorsen, respectively). The roles ‑if any‑ of ANGPTL3, PCSK9, and Apo CIII in HGSOC are unclear. Moreover, levels of these lipid‑modulating factors have never been reported before in HGSOC. In this study, circulating levels of ANGPTL3, PCSK9, and Apo CIII, along with lipid profiles, are examined to verify whether one or many of these lipid‑regulating factors are associated with HGSOC. Methods ELISA kits were used to measure ANGPTL3, PCSK9 and Apo CIII levels in plasma samples from 31 women with HGSOC and 40 women with benign ovarian lesions (BOL) before treatment and surgery. A Roche Modular ana‑ lytical platform measured lipid panels, Apo B and Lp(a) levels. Results ANGPTL3 levels were higher in women with HGSOC (84 ng/mL, SD: 29 ng/mL, n = 31) than in women with BOL (67 ng/mL, SD: 31 ng/mL, n = 40; HGSOC vs. BOL P = 0 . 019) . Associations between the lipid panel and ANGPTL3, and the inverse relationship between HDL‑cholesterol and triglycerides, were present in women with BOL but not with HGSOC. PCSK9 and Apo CIII were not associated with HGSOC. Conclusions In this cohort of 71 women, ANGPTL3 levels were increased in HGSOC patients. The presence of HGSOC disrupted the classic inverse relationship between HDL and triglycerides, as well as the association between the lipid panel and ANGPTL3 . These associations were only maintained in cancer‑free women. Given the availability of Evi‑ nacumab, a therapeutic antibody against ANGPTL3, the current finding prompts an assessment of whether ANGPTL3 inhibition has therapeutic potential in HGSOC. Keywords ANGPTL3, Evinacumab, PCSK9, Apo CIII, Lp(a), Lipid profile, High‑grade serous ovarian cancer *Correspondence: Anne Gangloff anne.gangloff.1@ulaval.ca; anne.gangloff@crchudequebec.ulaval.ca Full list of author information is available at the end of the article © Crown 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the mate‑ rial. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/)[. The Creative Commons Public Domain Dedication waiver (](http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Do

FAQs

What question does the study investigate about ANGPTL3, PCSK9, and Apo CIII in HGSOC?

The study assesses whether pre-operative circulating levels of ANGPTL3, PCSK9, and Apo CIII—together with lipid profiles—are associated with HGSOC.

How were ANGPTL3, PCSK9, and Apo CIII levels measured and in whom?

ELISA kits measured ANGPTL3, PCSK9, and Apo CIII in plasma from 31 women with HGSOC and 40 women with benign ovarian lesions before treatment and surgery.

What were the main findings regarding ANGPTL3 and other lipid-modulating factors?

ANGPTL3 was higher in women with HGSOC than in those with benign ovarian lesions, while PCSK9 and Apo CIII showed no association with HGSOC.

Sep 22, 2026

Upload by Anda